Page 50 - Annual report 2021-22
P. 50
Annual Report 2021-22 |
development of tools that allow deployment of the technology in remote locations, for instance the
development of cell phone applications for use with the diagnostics and the development of better
delivery systems for improving the efficiency of gene editing. He has also engaged with several medical
institutions to hand hold clinical trials for gene editing in retinal diseases, besides sickle cell anemia.
33
”To ask questions, to search for answers, to do research – I mean re-
search in nature, what is already there, but has not been revealed so
far is the most fascinating and the most exciting thing we can dream
of doing and what we would like to continue doing”. — Rolf M.
Zinkernagel
